This finding was further demonstrated in a validation cohort of 63 RCC patients treated with anti-PD1/PD-L1 immunotherapies alone or in combination with anti-CTLA4 antibody [48]. The gene discussed is PDCD1; the disease is renal cell adenocarcinoma.